Endothelium
Dipyridamole has effects on both platelets and the endothelium. Dipyridamole inhibits cell uptake of adenosine, which increases intraplatelet cAMP, an inhibitor of platelet aggregation.
Dipyridamole also inhibits breakdown of cyclic GMP, which also inhibits platelet aggregation.
Unlike the prolonged effect of ASA, the effects of dipyridamole are shorter, requiring either multiple daily dosing or more prolonged plasma concentrations.
References
Zahavi M, Zahavi J, Kakkar VV. Thromb Haemost 1984, 52: 205-209.
PubMed Abstract
Salzman EW. N Engl J Med 1972, 286: 358-363.
PubMed Abstract
Adams GA, Feuerstein IA. Thromb Haemost 1984, 52: 45-49.
PubMed Abstract
Souness et al. Biochem J 1990, 266: 127-132.
PubMed Abstract
Radomski MW, Palmer RMJ, Moncada S. Biochem Biophys Res Commun 1987,148: 1482-1489.
PubMed Abstract
Venturini CM, Weston LK, Kaplan JE. Am J Physiol 1992, 63: H606-H612.
PubMed Abstract
Boehringer Ingelheim Data on File.
